Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

Dong Wook Kim, Nan Wu, Young Chul Kim, Pei Feng Cheng, Ryan Basom, Dongkyoon Kim, Colin T. Dunn, Anastasia Y. Lee, Keebeom Kim, Chang Sup Lee, Andrew Singh, Adi F. Gazdar, Chris R. Harris, Robert N. Eisenman, Kwon Sik Park, David MacPherson

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


Small cell lung cancer (SCLC) is a devastating neuroendocrine carcinoma. MYCL (L-Myc) is frequently amplified in human SCLC, but its roles in SCLC progression are poorly understood. We isolated preneoplastic neuroendocrine cells from a mouse model of SCLC and found that ectopic expression of L-Myc, c-Myc, or N-Myc conferred tumorforming capacity. We focused on L-Myc, which promoted pre-rRNA synthesis and transcriptional programs associated with ribosomal biogenesis. Deletion of Mycl in two genetically engineered models of SCLC resulted in strong suppression of SCLC. The high degree of suppression suggested that L-Myc may constitute a therapeutic target for a broad subset of SCLC. We then used an RNA polymerase I inhibitor to target rRNA synthesis in an autochthonous Rb/p53-deleted mouse SCLC model and found significant tumor inhibition. These data reveal that activation of RNA polymerase I by L-Myc and other MYC family proteins provides an axis of vulnerability for this recalcitrant cancer.

Original languageEnglish (US)
Pages (from-to)1289-1299
Number of pages11
JournalGenes and Development
Issue number11
StatePublished - Jun 1 2016


  • Neuroendocrine
  • Oncogene
  • Progression
  • Ribosome biogenesis
  • Transcription factor

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology


Dive into the research topics of 'Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer'. Together they form a unique fingerprint.

Cite this